HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private Equity Firm Yellow Wood Plans Refresh For Suave Beauty, Hair Products In US, Canada

Executive Summary

Suave hair and beauty brand getting new home in US and Canada at private equity firm Yellow Wood Partners, which plans to grow line through innovation, marketing and distribution. Unilever maintains ownership in other regions.

You may also be interested in...



Unilever Delivers Q3 Growth On Pricing As US, European Consumers Tighten Purse Strings

In Europe in particular “consumer sentiment is deteriorating,” CFO Graeme Pitkethly said during the firm’s 27 October third-quarter earnings call. Unilever has more pricing actions planned but recognizes that consumers are having to make trade-offs due to inflation and private label is gaining share in some product categories.

Unilever Vows No GSK-Sized Ventures For Foreseeable Future, Commits To Existing Brands In 2022

Opening the company’s fiscal 2021 full-year earnings call, Unilever leadership assured investors it will not make any GSK-sized offers in the foreseeable future as it commits to organic growth and reshaping its portfolio more surgically through bolt-on deals and selective disposals.

RB Shows Scholl The Door, While Welcoming In Biofreeze

Reckitt is refocusing its consumer health portfolio by offloading the troubled Scholl brand and acquiring fast-growing US topical analgesic Biofreeze.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel